Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03609840 · ClinicalTrials.gov registry record
Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 25
- Enrollment target
NCT03609840: Completed study, sponsored by University of California, San Francisco.
NCT03609840 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03609840 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
Thiotepa is a chemotherapy drug used extensively in bone marrow transplantation. Thiotepa is a prodrug that undergoes metabolic conversion in the liver by CYP2B6 and CYP3A4 to its primary active metabolite, triethylene phosphoramide (TEPA). The goal of this study is to determine what causes some children to have different drug concentrations of thiotepa and TEPA in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that certain clinical and genetic factors cause changes in thiotepa and TEPA drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.
Primary Outcome
Area-under-the-curve (AUC) will be derived from the empirical Bayes estimates of individual clearance
Interventions
- DRUG Thiotepa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-05-24 |
| Est. Completion | 2023-07-31 |
What the finished NCT03609840 record still lists
NCT03609840 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Thiotepa is the first listed.
NCT03609840 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03609840 about?
NCT03609840 is a clinical study titled "Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients". Thiotepa is a chemotherapy drug used extensively in bone marrow transplantation. Thiotepa is a prodrug that undergoes metabolic conversion in the liver by CYP2B6 and CYP3A4 to its primary active metabolite, triethylene phosphoramide (TEPA). The goal of this study is to determine what causes some chi...
What is the current status of trial NCT03609840?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2017-05-24. Estimated completion is 2023-07-31.
What interventions are being tested in trial NCT03609840?
The interventions under investigation include: Thiotepa (DRUG).
Who is sponsoring clinical trial NCT03609840?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI